Environmental Mastitis (Coliform Mastitis - Escherichia coli, Klebsiella spp., Streptococcus uberis)

Environmental mastitis is an inflammation of the bovine mammary gland caused by pathogens that reside in the cow's environment, including bedding, manure, soil, and water. The primary agents are gram-negative coliforms (Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca) and the gram-positive Streptococcus uberis. Unlike contagious mastitis (e.g., Streptococcus agalactiae, Staphylococcus aureus), environmental pathogens do not primarily spread from cow to cow during milking; instead, they opportunistically invade the teat canal between milkings or during milking when hygiene is compromised. The disease manifests in two clinical forms: (1) subclinical or mild clinical mastitis with elevated somatic cell count (SCC) and mild milk abnormalities, and (2) severe acute or peracute mastitis characterized by systemic signs such as fever, depression, anorexia, dehydration, and in severe coliform cases, endotoxemia, septic shock, and death. Environmental mastitis is a major economic burden in dairy herds, causing milk loss, treatment costs, increased culling, and reduced fertility. It is particularly prevalent in high-producing dairy cows during the early lactation and dry-off periods, and in facilities with poor bedding management, inadequate ventilation, and high stocking density. The disease is a leading cause of antibiotic use in dairy farms, raising concerns about antimicrobial resistance and milk residue violations.

The primary etiological agents of environmental mastitis are gram-negative coliform bacteria and the gram-positive Streptococcus uberis. Coliforms include Escherichia coli (especially strains with K1, K5, and O antigens), Klebsiella pneumoniae, and Klebsiella oxytoca. These bacteria are ubiquitous in the environment, found in feces, contaminated bedding (organic materials like sawdust, straw, manure solids), and water. Virulence factors of E. coli include endotoxin (lipopolysaccharide, LPS) in the outer membrane, fimbriae for adhesion, and capsular polysaccharides that resist phagocytosis. Klebsiella species produce a thick polysaccharide capsule that enhances survival in the udder and resistance to host defenses. Streptococcus uberis is a gram-positive coccus that can survive in the environment for extended periods, especially in organic matter. It produces enzymes such as hyaluronidase and streptokinase that facilitate tissue invasion, and it can form biofilms, making it resistant to antimicrobials and host immune responses. Other less common environmental pathogens include Enterococcus spp., Trueperella pyogenes (often associated with summer mastitis), and yeast/fungi (e.g., Candida spp.) in cases of contaminated intramammary infusions. The etiology is influenced by management practices: sawdust bedding is a reservoir for Klebsiella, while straw and manure solids favor E. coli and S. uberis. Poor milking hygiene, teat end damage, and immunosuppression (e.g., negative energy balance, hypocalcemia) increase susceptibility.

Environmental mastitis occurs worldwide and is more prevalent in intensive dairy systems with year-round housing compared to pasture-based systems. The incidence is highest during the periparturient period (first 2 weeks of lactation) and at dry-off, when the udder is particularly vulnerable. High-producing dairy cows (e.g., Holstein-Friesian) are at greater risk due to high milk yield, which increases teat canal patency and milking frequency. Parity also plays a role: older cows (≥3rd lactation) have higher prevalence due to cumulative udder damage and immune senescence. Seasonality is observed: coliform mastitis peaks in summer months, associated with heat stress and increased bacterial growth in bedding; S. uberis mastitis may increase in wet, humid conditions. Herd-level risk factors include large herd size, free-stall housing with organic bedding, inadequate bedding replenishment, poor ventilation, high stocking density, and lack of proper dry cow therapy. Morbidity rates can reach 30-50% in affected herds, with clinical cases occurring in 5-10% of cows per lactation. Mortality is low (1-3%) but can be higher in peracute coliform cases with septic shock. Economic losses are substantial: each clinical case costs $200-400 (USD) due to milk loss, treatment, discarded milk, and increased culling risk. Subclinical infections contribute to elevated bulk tank SCC, leading to milk quality penalties.

The pathogenesis of environmental mastitis begins with bacterial entry through the teat canal, facilitated by teat end damage, incomplete teat sphincter closure, or bacterial multiplication in teat canal keratin. Once in the cistern, bacteria adhere to mammary epithelial cells and multiply, releasing toxins and metabolic products. For coliforms, the key event is the release of endotoxin (LPS) from the bacterial cell wall upon lysis. LPS triggers a massive release of pro-inflammatory cytokines (TNF-α, IL-1, IL-6) from macrophages and epithelial cells, leading to a systemic inflammatory response syndrome (SIRS). This cascade causes vasodilation, increased vascular permeability, and recruitment of neutrophils into the mammary gland. Neutrophil infiltration results in increased SCC and milk clotting. In severe cases, endotoxin enters the bloodstream, causing fever, hypotension, tachycardia, and shock. The inflammatory response also damages mammary tissue, leading to reduced milk production and potential permanent fibrosis. For S. uberis, the pathogenesis is less acute but involves tissue invasion and biofilm formation, leading to chronic or recurrent infections. The bacteria produce enzymes that degrade tissue components, and the host response is characterized by a predominantly neutrophilic inflammation. The severity of clinical signs correlates with the bacterial strain, inoculum size, and host immune status. Cows with impaired immune function (e.g., negative energy balance, hypocalcemia, ketosis) are more susceptible to severe disease.

Intrinsic factors: (1) High milk yield – increases teat canal diameter and milking frequency, enhancing bacterial entry; (2) Parity – older cows have more udder damage and reduced immune function; (3) Transition period – immunosuppression due to negative energy balance, hypocalcemia, and cortisol elevation; (4) Genetic predisposition – some cows have weaker teat sphincter tone; (5) Teat end lesions – caused by improper milking machine function or trauma, providing entry points. Extrinsic factors: (1) Bedding management – organic bedding (sawdust, straw) supports bacterial growth; wet, dirty bedding increases exposure; (2) Housing environment – poor ventilation, high humidity, and overcrowding increase bacterial load; (3) Milking hygiene – inadequate teat disinfection, wet udders, and contaminated milking equipment; (4) Milking machine function – improper vacuum levels, pulsation, or liner slips cause teat damage and backflow; (5) Dry cow management – lack of dry cow therapy or poor dry cow environment; (6) Nutrition – vitamin E and selenium deficiency impair immune function; excessive dietary protein increases nitrogen in manure, promoting bacterial growth; (7) Heat stress – suppresses immune response and increases bacterial proliferation in bedding.

Clinical signs vary from mild to peracute. Mild cases: abnormal milk (flakes, clots, watery appearance), slight udder swelling, and no systemic signs. Moderate cases: visible udder inflammation (heat, swelling, redness, pain), milk abnormalities, and mild systemic signs (fever up to 40.5°C, reduced appetite). Severe cases (peracute coliform mastitis): sudden onset of severe systemic illness – high fever (41-42°C), depression, anorexia, tachycardia (100-120 bpm), tachypnea, dehydration, cold extremities, and recumbency in terminal stages. The affected quarter is swollen, hard, and painful; milk is serous or bloody with flakes. In S. uberis infections, clinical signs may be milder but can progress to chronic fibrosis. On herd examination, affected cows may show reduced rumen motility, decreased milk yield, and elevated SCC. In severe cases, signs of endotoxemia include injected mucous membranes, prolonged capillary refill time (>2 seconds), and diarrhea. In peracute cases, death can occur within 12-24 hours due to septic shock. Subclinical infections are detected by elevated SCC (>200,000 cells/mL) without visible milk changes.

1. Contagious mastitis (Streptococcus agalactiae, Staphylococcus aureus): Typically spread during milking; chronic, subclinical; milk culture distinguishes; contagious pathogens often cause high SCC but less severe systemic signs. 2. Summer mastitis (Trueperella pyogenes, Peptostreptococcus indolicus): Occurs in dry cows and heifers during summer; foul-smelling, purulent discharge; flies are vectors; severe udder swelling and systemic signs. 3. Mycoplasma mastitis (Mycoplasma bovis): Highly contagious; affects multiple quarters; severe agalactia; systemic signs; culture on special media. 4. Traumatic udder injury: History of trauma; localized swelling, hematoma; no systemic signs unless infection secondary. 5. Toxic mastitis due to other gram-negative bacteria (e.g., Pseudomonas, Serratia): Similar to coliform mastitis; culture identifies. 6. Milk fever (clinical hypocalcemia): Occurs in early lactation; recumbency, muscle weakness, but no udder inflammation; responds to calcium therapy. 7. Acute coliform mastitis vs. acute toxic metritis: Both cause systemic signs; uterine examination and vaginal discharge differentiate. 8. Clostridial mastitis (Clostridium perfringens): Rare but rapidly fatal; gas gangrene in udder; crepitus on palpation; severe toxemia. 9. Bovine respiratory disease (BRD): Fever and depression but no udder signs; respiratory auscultation and nasal discharge. 10. Peritonitis: Abdominal pain, fever, but udder normal; rectal palpation and ultrasound.

Step 1: Herd history – assess bedding type, hygiene, milking procedures, recent mastitis incidence, and bulk tank SCC. Step 2: Individual cow examination – perform thorough physical exam, including temperature, heart rate, respiratory rate, rumen motility, and udder palpation. Step 3: Strip cup test – evaluate milk for flakes, clots, color, and consistency. Step 4: California Mastitis Test (CMT) – semi-quantitative estimate of SCC; score 0-3. Step 5: Milk sample collection for bacteriology – aseptically collect milk from affected quarter before treatment; submit for culture and sensitivity. Step 6: Somatic cell count (SCC) – individual cow SCC via DHIA or on-farm testing; >200,000 cells/mL indicates infection. Step 7: Blood tests – complete blood count (CBC) to assess leukopenia/leukocytosis; serum chemistry including calcium, magnesium, phosphorus, BHB, and NEFA to evaluate metabolic status. Step 8: In severe cases, blood culture may be indicated. Step 9: Ultrasonography of the udder – can assess tissue damage, abscessation, or fibrosis. Step 10: Response to treatment – monitor clinical improvement and milk culture clearance. Step 11: Herd-level diagnostics – evaluate milking machine function, teat end condition, and environmental bacterial counts (bedding cultures).

Milk: Elevated SCC (>200,000 cells/mL; often >1,000,000 in clinical cases). CMT positive (score ≥2). Milk culture yields the causative organism (E. coli, Klebsiella, S. uberis). Blood: In acute coliform mastitis, CBC may show leukopenia (neutropenia with degenerative left shift) due to endotoxin-induced margination, followed by leukocytosis in recovery. Fibrinogen may be elevated (>700 mg/dL) indicating inflammation. Serum chemistry: Hypocalcemia (<8.0 mg/dL or <2.0 mmol/L) may be present due to endotoxin-induced calcium shifts. Hypophosphatemia (<4.0 mg/dL) is common. Hyperglycemia initially, then hypoglycemia in severe cases. Elevated BHB (>1.2 mmol/L) indicates ketosis, a risk factor. NEFA >0.4 mmol/L in transition cows indicates negative energy balance. Blood gas may show metabolic acidosis with respiratory compensation in shock. Rumen fluid analysis (if rumen stasis): pH <5.5 indicates ruminal acidosis, which may be concurrent. Milk electrolytes (sodium, chloride) may be elevated in mastitis, but not routinely measured.

Ultrasonography of the udder: In acute mastitis, the affected quarter may show increased echogenicity of the parenchyma, fluid accumulation, and thickened septa. Abscesses appear as hypoechoic cavities with hyperechoic walls. Chronic cases show fibrosis (hyperechoic areas). Thoracic ultrasound may be indicated if respiratory signs are present to rule out pneumonia. Abdominal ultrasound can assess rumen motility and rule out other causes of systemic illness. Radiography is rarely used for mastitis but may be useful to detect radiopaque foreign bodies in the teat if trauma is suspected. Mammography is not used in cattle. In research settings, contrast-enhanced ultrasound can assess tissue perfusion, but it is not practical in the field.

Milk cytology: Smears of milk sediment show numerous neutrophils, often degenerate, with intracellular bacteria (especially in coliform mastitis). Macrophages and epithelial cells may be present. Histopathology of udder tissue (from biopsy or necropsy): Acute mastitis shows intense neutrophilic infiltration in alveoli and interstitium, edema, hyperemia, and necrosis of epithelial cells. In coliform mastitis, there is often severe tissue necrosis and hemorrhage. Chronic S. uberis mastitis shows fibrosis, mononuclear cell infiltration, and alveolar atrophy. Histopathology of other organs in fatal cases may show signs of endotoxemia: pulmonary edema, hepatic congestion, and renal tubular necrosis. Udder biopsy is rarely performed antemortem due to risk of hemorrhage and infection, but it can be done for research or chronic cases.

Treatment goals: eliminate infection, control inflammation, and provide supportive care. For mild to moderate cases: (1) Intramammary antibiotics – for coliform mastitis, efficacy is limited; however, ceftiofur hydrochloride (125 mg per quarter) or amoxicillin-clavulanate (200 mg per quarter) may be used. For S. uberis, penicillin-based intramammary products (e.g., procaine penicillin G 100,000 IU per quarter) are effective. Administer every 12-24 hours for 2-3 days. (2) Systemic antibiotics – for severe cases or when there is systemic involvement: ceftiofur (2.2 mg/kg IM or SC q24h for 3-5 days), oxytetracycline (10 mg/kg IV or IM q24h), or ampicillin (10-20 mg/kg IM or SC q12h). (3) Anti-inflammatory therapy – flunixin meglumine (1.1-2.2 mg/kg IV or IM q24h for 1-3 days) to reduce fever and inflammation; aspirin (100 mg/kg PO q12h) may be used but is less potent. (4) Fluid therapy – for dehydrated or toxic cows: IV isotonic fluids (e.g., lactated Ringer's solution) at 20-40 mL/kg over 1-2 hours, then maintenance. Hypertonic saline (7.2% NaCl, 4-5 mL/kg IV over 5-10 minutes) followed by oral water can rapidly expand plasma volume. (5) Calcium supplementation – if hypocalcemic: 500 mL of 23% calcium borogluconate SC or IV slowly. (6) Supportive care – frequent milking (every 6-8 hours) to remove toxins and bacteria; oxytocin (20-40 IU IM) may be used to facilitate milk letdown, but avoid in severe endotoxemia. (7) In peracute cases, consider IV dexamethasone (0.1-0.2 mg/kg) for shock, but use with caution due to immunosuppression. (8) Nutritional support – ensure access to fresh water and high-quality feed; propylene glycol (250-300 mL PO q12h) if ketosis is present. (9) Dry cow therapy – for dry cows, use long-acting intramammary preparations (e.g., cloxacillin 500 mg) at dry-off to prevent new infections.

Prognosis depends on the pathogen, severity, and promptness of treatment. For mild to moderate S. uberis mastitis, prognosis is good with appropriate therapy; cure rates are 70-80%. For coliform mastitis, mild cases often resolve spontaneously, but severe cases have a guarded prognosis. Mortality in peracute coliform mastitis is 10-20% despite treatment. Factors indicating poor prognosis: recumbency, severe dehydration, prolonged capillary refill time, marked leukopenia, and lack of response within 24-48 hours. Milk production in the affected quarter may never fully recover due to tissue damage; cows may lose 10-20% of milk yield in that quarter. Culling risk is increased, especially if the cow develops chronic mastitis or reduced fertility. Negative prognostic biomarkers include persistent fever >24 hours, elevated blood lactate (>4 mmol/L), and severe hypocalcemia. With early and aggressive treatment, many cows can recover, but the affected quarter may have elevated SCC for the remainder of lactation.

Individual cow: Recheck clinical signs daily during treatment; monitor temperature, appetite, and milk yield. Repeat milk culture 2-3 weeks after treatment to confirm bacteriological cure. Monitor SCC monthly via DHIA; if SCC remains >200,000 cells/mL, consider culling or dry cow therapy. Herd-level: Review milking procedures, bedding management, and ventilation. Implement a mastitis control plan: (1) Maintain clean, dry bedding – replace bedding regularly, use inorganic bedding (sand) if coliform problems persist. (2) Improve milking hygiene – pre-dip with iodine-based teat disinfectant, dry udders thoroughly, post-dip after milking. (3) Milking machine maintenance – check vacuum levels, pulsation, and liner condition quarterly. (4) Dry cow therapy – use blanket dry cow therapy with long-acting antibiotics and teat sealants. (5) Vaccination – consider J-5 E. coli vaccine for coliform mastitis in herds with high incidence; administer at dry-off and 2-4 weeks before calving. (6) Monitor bulk tank SCC and clinical mastitis incidence; set targets (<150,000 cells/mL). (7) Cull chronic mastitis cows. (8) Provide adequate nutrition, especially vitamin E and selenium (1000 IU and 3 mg/kg DM, respectively) to enhance immunity.

Pearls: (1) In peracute coliform mastitis, the quarter may be cold and blue due to ischemia; this indicates severe endotoxemia and poor prognosis. (2) Frequent milking (every 6 hours) is more beneficial than antibiotic therapy alone in coliform mastitis because it removes endotoxin and bacteria. (3) Hypertonic saline (7.2% NaCl) is excellent for rapid fluid resuscitation in toxic cows; administer 4-5 mL/kg IV over 5-10 minutes, then provide free-choice water. (4) Flunixin meglumine is the NSAID of choice for endotoxemia; avoid corticosteroids in early lactation due to milk production suppression. (5) In S. uberis mastitis, penicillin is the drug of choice; resistance is rare. (6) Always culture milk before starting antibiotics to guide therapy and avoid unnecessary antimicrobial use. Pitfalls: (1) Do not use intramammary antibiotics in severe coliform mastitis as the primary treatment; they are ineffective and may increase endotoxin release. (2) Avoid overuse of systemic antibiotics in mild cases; many coliform infections self-cure. (3) Do not forget to check for concurrent hypocalcemia and ketosis; these can worsen prognosis. (4) Do not milk a severely toxic cow too frequently without fluid support; it can worsen dehydration. (5) Do not use teat sealants in cows with existing mastitis. (6) Do not ignore herd-level risk factors; treating individual cows without addressing bedding and milking hygiene will lead to recurrence.

Based on Plumb's Veterinary Drug Handbook and AABP guidelines: (1) Ceftiofur hydrochloride (e.g., Excede, Spectramast LC): Intramammary: 125 mg per quarter q12h for 2-3 doses; Systemic: 2.2 mg/kg SC or IM q24h for 3-5 days. Milk withdrawal: 72 hours (intramammary) or 0 days (systemic if labeled). Meat withdrawal: 13 days (systemic). (2) Amoxicillin-clavulanate (e.g., Synulox LC): Intramammary: 200 mg amoxicillin + 50 mg clavulanate per quarter q12h for 3 doses. Milk withdrawal: 84 hours. Meat withdrawal: 7 days. (3) Procaine penicillin G (e.g., Mastiject): Intramammary: 100,000 IU per quarter q12h for 3-4 doses. Milk withdrawal: 72 hours. Meat withdrawal: 10 days. (4) Oxytetracycline (e.g., Liquamycin LA-200): Systemic: 10 mg/kg IM or SC q24h for 3-5 days. Milk withdrawal: 96 hours (IM) or 72 hours (SC). Meat withdrawal: 28 days. (5) Flunixin meglumine (e.g., Banamine): 1.1-2.2 mg/kg IV or IM q24h for 1-3 days. Milk withdrawal: 36 hours. Meat withdrawal: 4 days. (6) Hypertonic saline (7.2% NaCl): 4-5 mL/kg IV over 5-10 minutes, once. No withdrawal. (7) Calcium borogluconate 23%: 500 mL SC or slow IV; monitor heart rate. No withdrawal. (8) Propylene glycol: 250-300 mL PO q12h for 2-3 days. No withdrawal. (9) Dexamethasone: 0.1-0.2 mg/kg IV or IM once; use with caution. Milk withdrawal: 72 hours. Meat withdrawal: 7 days. (10) Oxytocin: 20-40 IU IM or IV; use only if needed. No withdrawal. Always follow label directions and consult your veterinarian for specific protocols.

Landmark studies: (1) A meta-analysis by Barkema et al. (1998) on mastitis incidence and risk factors showed that environmental mastitis is strongly associated with bedding type and hygiene. (2) A study by Hogan and Smith (2003) demonstrated that J-5 E. coli vaccination reduces the severity of clinical coliform mastitis but not the incidence. (3) Research by Bradley and Green (2001) highlighted the importance of dry cow therapy and teat sealants in preventing environmental mastitis during the dry period. (4) A randomized controlled trial by Roberson et al. (2004) found that pre-milking teat disinfection and dry udder preparation significantly reduced new intramammary infections. (5) Studies on S. uberis mastitis by Zadoks et al. (2003) showed that the pathogen can persist in the environment and cause recurrent infections, emphasizing the need for environmental control. (6) Consensus guidelines from the National Mastitis Council (NMC) and the American Association of Bovine Practitioners (AABP) recommend a comprehensive mastitis control program including milking hygiene, bedding management, and vaccination. (7) A study by Leslie and Petersson-Wolfe (2012) on antimicrobial therapy for coliform mastitis concluded that systemic antibiotics are not always necessary, and supportive care is paramount. (8) Research on the economic impact by Halasa et al. (2007) estimated the cost per clinical case at $200-400, with severe cases costing more. These findings underscore the importance of prevention and early intervention.